Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | HTR2B | P41595 | 4/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23222283 | 0.88 | NR1H2 (0.37) | HTR2CHTR2AHTR2BNR1H3NR1H2 | |
| SCHEMBL18997805 | 0.85 | HTR2C (0.44) | HTR2CHTR2AHTR2BNR1H3NR1H2 | |
| SCHEMBL18997802 | 0.71 | HTR2C (0.45) | HTR2CHTR2AHTR2BNR1H3NR1H2 | |
| SCHEMBL18997803 | 0.68 | HTR2C (0.46) | HTR2CHTR2AHTR2BNR1H3NR1H2 | |
| SCHEMBL23764796 | 0.67 | HTR2C (0.54) | HTR2CHTR2AHTR2BRBP4 | |
| SCHEMBL12844377 | 0.64 | PIK3C3 (0.43) | — | |
| SCHEMBL19002637 | 0.63 | PDE2A (0.40) | — | |
| SCHEMBL30455410 | 0.62 | HTR2C (0.60) | HTR2CHTR2AHTR2BNR1H3NR1H2 | |
| SCHEMBL29906021 | 0.62 | HTR2C (0.60) | HTR2CHTR2AHTR2BNR1H3NR1H2 | |
| SCHEMBL12141864 | 0.61 | HRH4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | HTR2C 4575/4885HTR2A 4536/4885HTR2B 4525/4885 |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | HTR2C 4176/4885HTR2A 4083/4885HTR2B 4127/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | HTR2C 4575/4885HTR2A 4536/4885HTR2B 4525/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | HTR2C 4575/4885HTR2A 4536/4885HTR2B 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.